MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma
Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · May 14, 2015
Trial Information
Current as of June 09, 2025
Unknown status
Keywords
ClinConnect Summary
This clinical trial is focused on finding new ways to diagnose and predict outcomes for patients with hepatocellular carcinoma (HCC), which is the most common type of liver cancer. The researchers are particularly interested in using small molecules called microRNAs (miRNAs) found in the blood as potential biomarkers. These miRNAs can be measured easily and might help doctors understand the disease better and monitor how well treatments are working. Unlike the current blood test for HCC, alpha-fetoprotein (AFP), which may not always be reliable after treatment, miRNAs could provide a more accurate picture of a patient's health.
To participate in this study, individuals must have a confirmed diagnosis of HCC, but there are no other specific exclusion criteria. Participants can expect to provide blood samples before and after their treatment, which will help researchers see how miRNA levels change and how they relate to tumor behavior. Overall, this trial aims to improve the way HCC is diagnosed and monitored, making it more effective for patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HCC, diagnosed by AASLD image criteriae or histopathologically.
- Exclusion Criteria:
- • Nil
About National Taiwan University Hospital
National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Trial Officials
Ja-Der Liang, Master
Principal Investigator
National Taiwan University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials